EPA’s risk evaluation for D4 (octamethylcyclotetrasiloxane, CAS 556-67-2) under TSCA Section 6 establishes a finding of unreasonable risk across multiple worker, consumer, and environmental conditions of use. For procurement teams sourcing silicone intermediates, silicone fluids, or formulated silicone products through a specialty chemical sourcing partner into US-bound manufacturing operations, this determination changes the supplier qualification conversation, the contract risk calculus, and the timeline for qualifying compliant alternatives.
The EU already restricted D4 and D5 cyclosiloxanes under REACH Annex XVII in wash-off cosmetics. The US EPA action under TSCA is the corresponding US regulatory track, arriving several years later but signaling the same direction for the world’s two largest regulated chemical markets.
What EPA’s D4 Risk Evaluation Found
EPA released its draft D4 risk evaluation in September 2025 under the Toxic Substances Control Act, with a final determination scheduled for April 2026 following peer review by the Science Advisory Committee on Chemicals (SACC). The finding of unreasonable risk is structured across three exposure categories, each with different procurement implications.
Worker risk (23 conditions of use): Unreasonable risk identified for workers manufacturing D4, processing D4 into products including adhesives, sealants, paints, and coatings, and applying those products in industrial and commercial settings. This category affects chemical manufacturers, compounders, and industrial applicators, not end consumers.
Consumer risk (1 condition of use): Paints and coatings containing D4 used by consumers. The single consumer COU narrows the direct restriction risk to finished product formulations, not the full D4 supply chain.
Environmental risk (7 conditions of use): D4 persistence and bioaccumulation in aquatic environments drove the environmental finding, mirroring the EU REACH reasoning for D4 and D5 restrictions. Seven COUs generate environmental exposure above EPA’s benchmark.
Which Silicone Applications Face the Highest Regulatory Exposure
The 23 worker COUs cover a wide range of industrial processing scenarios, but the procurement risk concentration falls into four application areas. Knowing where your D4 consumption sits determines how urgently you need to act.
Adhesives and sealants: D4 is used as a processing solvent and intermediate in silicone sealant manufacturing. Both the manufacturing worker exposure and the downstream processing worker exposure are captured in EPA’s unreasonable risk finding. Formulators in this space face the highest near-term risk management obligation.
Paints and coatings: Both worker and consumer COUs are flagged, making this the only application where EPA’s finding spans the full exposure chain from manufacturing to end use. Formulators incorporating D4 into architectural or industrial coatings face the broadest regulatory pressure.
Silicone polymer manufacturing: D4 is the primary feedstock for silicone polymers, including PDMS (polydimethylsiloxane) and higher-functionality silicones. The manufacturing worker COU for this application is among the highest-volume D4 uses globally. Downstream buyers purchasing PDMS and other D4-derived silicone fluids should request confirmation of manufacturing process compliance status from their suppliers.
Personal care intermediates: D4 is used as a processing intermediate and as a direct ingredient in some personal care formulations. The EU restriction in wash-off cosmetics already closed the EU market for D4-containing rinse-off products. US EPA’s consumer COU finding in paints and coatings does not directly replicate the EU personal care restriction, but the broader unreasonable risk determination creates regulatory pressure on US personal care manufacturers to proactively address D4 content regardless of COU specificity.
TSCA Section 6 Risk Management: What Comes Next and When
An EPA finding of unreasonable risk under TSCA Section 6 does not immediately prohibit use. It triggers a mandatory risk management rulemaking process, which EPA must initiate within 1 year of the final determination and complete within 2 years. This timeline gives procurement teams a window to prepare, but not a window to ignore.
The risk management rule EPA develops for D4 can take several forms: prohibition on specific COUs, required exposure controls (engineering controls, PPE, ventilation standards), concentration limits in finished products, or downstream notification requirements. The TSCA phthalate risk evaluations from 2024 provide the most recent comparison: EPA prohibited certain phthalate uses in children’s products outright while imposing exposure control requirements on industrial uses rather than prohibiting them.
For D4, the most likely outcome based on EPA’s track record with similar chemicals: industrial worker COUs will face engineering and administrative control requirements before outright prohibition, while any COUs involving direct consumer exposure face a higher probability of use restriction or concentration limits. The personal care sector’s experience with EU D4/D5 restrictions provides a practical model of what US restrictions could look like operationally.
The procurement implication is timing. Procurement teams that begin qualifying compliant alternatives now, before the risk management rule is finalized, will have 18 to 24 months of runway to qualify alternatives, run production trials, and update regulatory submissions. Teams that wait for the final rule will face the qualification timeline compressed against the compliance deadline.
D5 and D6: The Rest of the Cyclosiloxane Regulatory Picture
Procurement teams addressing D4 should simultaneously assess their D5 (decamethylcyclopentasiloxane) and D6 (dodecamethylcyclohexasiloxane) exposure. Both EU and US regulatory trajectories treat the cyclosiloxane family similarly, and a supplier-by-supplier D4 substitution that inadvertently increases D5 content simply defers the compliance problem.
The EU has restricted D5 alongside D4 in wash-off cosmetics under REACH Annex XVII, applying the same 0.1% concentration limit. EU restrictions on D5 in leave-on cosmetics have been under consideration, with ECHA SVHC candidate list additions signaling likely future scope expansion. For formulations supplying both EU and US markets, a cyclosiloxane-neutral substitution strategy (replacing with non-cyclic silicones or non-silicone alternatives) is more durable than substituting D4 with D5.
D6 does not currently carry the same regulatory profile as D4 and D5, but its structural similarity means it receives scientific scrutiny whenever D4 and D5 are evaluated. Procurement teams should obtain cyclosiloxane content declarations from silicone suppliers covering D4, D5, and D6 as a package, not just the most immediately regulated species.
Sourcing Silicone Ingredients Through Raw Source
Silicone teams in the D4 transition are doing two things at once: keeping current formulations supplied while qualifying compliant alternatives, usually on a tight schedule. The alternatives carry meaningful price premiums and longer lead times than the cyclosiloxane-based products they replace.
Raw Source’s silicones portfolio at container-load scale covers the categories sitting directly in the path of D4 regulatory pressure: silicone fluids (PDMS-based), silicone surfactants, silicone emulsions, antifoam formulations, and silanes. For teams in the D4 transition, that means sourcing both the current D4-derived products (where the market still allows them) and compliant alternatives through one supply partner, with the documentation your compliance file needs.
The D4 compliance documentation requirement has evolved beyond a simple CoA. Buyers supplying regulated markets and formulators of beauty and personal care ingredients now need supplier attestations covering cyclosiloxane content (D4, D5, D6 as a family), manufacturing process GMP status for the specific COUs implicated in EPA’s finding, and, for personal care applications, REACH compliance declarations covering the EU restriction thresholds. Raw Source’s supply arrangements for silicone ingredients include the documentation package your compliance team needs, not just the standard commercial documents.
Container-load procurement for silicone fluids and formulated silicone products starts at 1 MT minimum, with FCL volumes providing the pricing and supply priority that multi-year D4 transition programs require. For procurement teams managing annual volumes across multiple silicone categories (antifoams, surfactants, fluids, emulsions), a consolidated supply arrangement reduces the fragmentation of managing separate compliance documentation requests and supplier qualification processes for each product family.
The NYSCC Suppliers’ Day 2026 analysis published by Raw Source covers the personal care sector’s parallel D4 and D5 transition in detail, including the specific alternative ingredient categories (branched hydrocarbons, bio-based esters, non-cyclic silicones) that personal care formulators are evaluating. For procurement teams in personal care, that analysis provides the substitution context this article’s regulatory focus does not cover in full.
Lead times for specialty silicone alternatives vary by product and origin. Non-cyclic silicone fluids from established producers typically run 8 to 10 weeks to order delivery for container-load volumes. Bio-based and hydrocarbon-based alternatives sourced as D4 substitutes carry similar lead times but require qualification runs that add 4 to 8 weeks to the effective procurement timeline. Starting the qualification process now, with an April 2026 final determination as the regulatory baseline, gives procurement teams the most workable runway before compliance deadlines attach to the risk management rule.
Pricing for compliant alternatives reflects both supply tightness and the current qualification premium. Alternatives to D4 in coatings and adhesives applications are trading at 15 to 25% above conventional D4-derived product pricing for comparable performance grades. That premium is expected to compress as alternative capacity scales, but teams locking annual contract volumes now are positioned better than those waiting for the premium to fall, which may not happen before the risk management rule’s compliance date.
Discuss your silicone sourcing requirements with Raw Source’s sourcing team, including D4 transition timelines, compliant alternative options, and container-load pricing by grade and origin.
Frequently Asked Questions
What did EPA find in its D4 risk evaluation under TSCA?
EPA's draft risk evaluation, published September 2025, determined that D4 (octamethylcyclotetrasiloxane) presents unreasonable risk of injury to human health across 23 worker conditions of use and one consumer condition of use (paints and coatings), and unreasonable environmental risk across seven conditions of use. The final risk evaluation was scheduled for April 2026. This determination triggers a mandatory TSCA Section 6 risk management rulemaking that EPA must initiate within 1 year of the final determination.
Which industries and applications are most directly affected by the D4 risk evaluation?
The highest-exposure applications are adhesives and sealants manufacturing, paints and coatings (both worker and consumer exposure), silicone polymer manufacturing, and personal care product formulation using D4 as an intermediate or ingredient. Procurement teams in these sectors face the most direct regulatory pressure. Industries using D4-derived silicone products without direct D4 handling (such as buyers of finished PDMS fluids) face secondary exposure through supplier compliance requirements and potential reformulation needs.
How does EPA's D4 evaluation relate to EU restrictions on D4 and D5?
The EU restricted D4 and D5 in wash-off cosmetics under REACH Annex XVII, applying a 0.1% concentration limit. EPA's TSCA action is a separate US regulatory track that evaluates D4 across a broader range of conditions of use, not limited to cosmetics. The EU action is already in force; the US TSCA risk management rule is still in the rulemaking process following the final determination. For procurement teams supplying both markets, the EU restriction requires immediate compliance action while the US rule requires advance planning.
What alternatives exist for D4 in regulated applications?
Available alternatives depend on the application. For personal care, non-cyclic silicones (linear PDMS variants), branched hydrocarbons, and bio-based esters provide D4-free formulation options with documented availability. For coatings and adhesives, silicone-modified polyesters and non-cyclic silicone fluids serve as functional substitutes in many formulations. Alternatives currently carry a 15 to 25% price premium over D4-derived products and require 8 to 14 weeks lead time. Qualification trials add 4 to 8 weeks to the effective procurement timeline.
Should procurement teams also assess D5 and D6 exposure now?
Yes. D5 (decamethylcyclopentasiloxane) carries the same EU REACH Annex XVII restriction as D4 in wash-off cosmetics. D6 (dodecamethylcyclohexasiloxane) faces increasing regulatory scrutiny given structural similarities. Formulation teams substituting D4 with D5 to address the EU wash-off restriction are deferring compliance risk rather than resolving it. Procurement teams should obtain cyclosiloxane content declarations from silicone suppliers covering D4, D5, and D6 as a family and evaluate substitution strategies that address the full cyclosiloxane regulatory trajectory.
What documentation should buyers request from silicone suppliers given the D4 risk evaluation?
Beyond the standard CoA and SDS, procurement teams should request: explicit cyclosiloxane content declarations (D4, D5, D6 concentrations in the supplied product), confirmation of manufacturing process compliance with applicable TSCA requirements for the relevant COUs, REACH Annex XVII compliance declarations for EU-destined shipments, and, for personal care applications, formulation-level attestations confirming D4 content below the applicable market threshold. These documents should be updated with each lot and retained as part of your regulatory compliance file.
